Replies to post #6395 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Current Insider Shareholdings and Options

[Updated for acquisitions by six directors on 12/28/07 in lieu
of all or part of their 2008 director’s compensation. Except
for the options issued this year (which can be tracked from
recent Form-4 filings), exercise prices of the various options
are spelled out in the DEF14a SEC filing for the 2007 annual
meeting. Essentially all options are currently underwater.]

 
  
 Executive Officers  
 Geoffrey Cox, CEO          277K shares   722K options 
 John Green, CFO            116K shares   307K options 
 Harry Meade, SVP Research  123K shares   268K options 
 Dan Woloshen, Gen. Counsel  88K shares   190K options 
 Greg Liposky, SVP Oprtns    57K shares   246K options 
 Dick Scotland, SVP Regltry  69K shares   129K options 
 -- 
 Six executive officers     730K shares 1,852K options

 
 Non-executive directors  
 Robert Baldridge             5K shares    75K options 
 Kenneth Bauer                 0 shares    38K options 
 Christian Béchon            18K shares    15k options 
 Francis Bullock             11K shares    74K options 
 James Geraghty              88K shares   163K options 
 Michael Landine               0 shares    38K options 
 Pamela McNamara              9K shares    53K options 
 Marvin Miller                8K shares    53K options 
 Alan Tuck                   14K shares    51K options 
 Mary Ann Gray               11K shares    15K options 
 -- 
 Ten non-executive directrs 164K shares   575K options

 
 All officers/directors     894K shares 2,427K options